Gregory Newby, PhD
- Johns Hopkins School of Medicine Faculty
Languages
- English
Gender
MaleAbout Gregory Newby
Primary Academic Title
Assistant Professor of Genetic Medicine
Background
Greg Newby is an Assistant Professor in the McKusick-Nathans Department of Genetic Medicine and jointly affiliated with the Department of Biomedical Engineering.
His research interests include the development of efficient genome editing tools to correct genetic disease mutations as well as studying the regulatory landscape of the genome to better understand and control gene expression.
Dr. Newby earned his bachelor's degree in Biological Sciences from Carnegie Mellon University and conducted research as a Fulbright Scholar in the laboratory of Andreas Plückthun at the University of Zürich. He studied at MIT with Susan Lindquist and Ahmed Khalil for his PhD. From 2017-2023, he was a postdoctoral fellow in the laboratory of David Liu at Harvard University and the Broad Institute. During his postdoctoral work, Dr. Newby developed editing tools and methods to treat disorders of the blood, heart, lung, central nervous system, retina, liver, and skin.
He began his laboratory at JHU in 2023 in order to advance new technology that combats the suffering caused by genetic disease.
Additional Academic Titles
Assistant Professor of Biomedical Engineering, Assistant Professor of Molecular Biology and Genetics
Lab Website
Newby Lab - Lab Website
Selected Publications
Newby GA, Liu DR. In vivo somatic cell base editing and prime editing. Mol Ther. 2021 Nov 3;29(11):3107-3124. doi: 10.1016/j.ymthe.2021.09.002. Epub 2021 Sep 10. PMID: 34509669; PMCID: PMC8571176
Newby GA, Yen JS, Woodard KJ, Mayuranathan T, Lazzarotto CR, Li Y, Sheppard-Tillman H, Porter SN, Yao Y, Mayberry K, Everette KA, Jang Y, Podracky CJ, Thaman E, Lechauve C, Sharma A, Henderson JM, Richter MF, Zhao KT, Miller SM, Wang T, Koblan LW, McCaffrey AP, Tisdale JF, Kalfa TA, Pruett-Miller SM, Tsai SQ, Weiss MJ, Liu DR. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature. 2021 Jul;595(7866):295-302. doi: 10.1038/s41586-021-03609-w. Epub 2021 Jun 2. PMID: 34079130; PMCID: PMC8266759
Mayuranathan T*, Newby GA*, Feng R, Yao Y, Mayberry KD, Lazzarotto CR, Li Y, Levine RM, Nimmagadda N, Dempsey E, Kang G, Porter SN, Doerfler PA, Zhang J, Jang Y, Chen J, Bell HW, Crossley M, Bhoopalan SV, Sharma A, Tisdale JF, Pruett-Miller SM, Cheng Y, Tsai SQ, Liu DR, Weiss MJ, Yen JS. Potent and uniform fetal hemoglobin induction via base editing. Nat Genet. 2023 Jul;55(7):1210-1220. doi: 10.1038/s41588-023-01434-7. Epub 2023 Jul 3. PMID: 37400614; PMCID: PMC10722557. *Co-first authors
Reichart D*, Newby GA*, Wakimoto H*, Lun M, Gorham JM, Curran JJ, Raguram A, DeLaughter DM, Conner DA, Marsiglia JDC, Kohli S, Chmatal L, Page DC, Zabaleta N, Vandenberghe L, Liu DR, Seidman JG, Seidman C. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat Med. 2023 Feb;29(2):412-421. doi: 10.1038/s41591-022-02190-7. Epub 2023 Feb 16. PMID: 36797483; PMCID: PMC9941048. *Co-first authors
Honors
- Pioneer Award, Cystic Fibrosis Foundation, 6/1/23
- Excellence Award in Collaboration / Support of Science, Broad Institute of MIT and Harvard, 12/1/22
Memberships
- American Society of Gene and Cell Therapy